quinazolines has been researched along with Fibrodysplasia Ossificans Progressiva in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Eekhoff, EMW; Keen, R; Smilde, BJ; Stockklausner, C; van Schoor, NM; von Delft, A; Whittaker, A; Yu, PB | 1 |
| Fischer, K; Haupt, J; Hildebrand, L; Hildebrandt, S; Kampfrath, B; Knaus, P; Stachelscheid, H | 1 |
| Bagarova, J; Bocobo, GA; Bullock, AN; Dey, D; Economides, AN; Huang, X; Kerr, G; Lee, A; Mohedas, AH; Place, ES; Sanderson, PE; Shen, Y; Smith, JC; Williams, E; Xia, DD; Yu, PB; Zheng, W | 1 |
| Hino, K; Horigome, K; Ikeya, M; Komura, S; Nagata, S; Nishio, M; Ohta, A; Okanishi, Y; Toguchida, J; Yamada, Y; Zhao, C | 1 |
1 trial(s) available for quinazolines and Fibrodysplasia Ossificans Progressiva
| Article | Year |
|---|---|
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Topics: Adolescent; Adult; Aged; Benzodioxoles; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Mutation; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Randomized Controlled Trials as Topic; Young Adult | 2022 |
3 other study(ies) available for quinazolines and Fibrodysplasia Ossificans Progressiva
| Article | Year |
|---|---|
ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.
Topics: Animals; Benzodioxoles; Induced Pluripotent Stem Cells; Mice; Myositis Ossificans; Quinazolines; Signal Transduction; Smad1 Protein; Smad5 Protein | 2021 |
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Animals; Benzodioxoles; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Gene Knock-In Techniques; Mice; Mice, Transgenic; Muscles; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Zebrafish | 2021 |
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Topics: Activin Receptors, Type I; Animals; Benzodioxoles; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Mice, SCID; Mice, Transgenic; Myositis Ossificans; Ossification, Heterotopic; Oxazoles; Pyrimidines; Quinazolines; Reproducibility of Results; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Urea | 2018 |